FDA drug-review deal may unravel as fiscal cliff looms
A $6.4 billion accord for U.S. drug and medical-device reviews is set to unravel just three months after taking effect as lawmakers squabble over budget cutbacks.
Eli Lilly and Co.
Articles
Eli Lilly aims to ramp up social media presence
The drugmaker recently drafted social media guidelines it hopes can help it expand its use of social media to more of its employees—without running afoul of regulators.
Lilly’s Alimta fails to extend survival in lung cancer study
Eli Lilly and Co. said Thursday that its cancer drug Alimta didn’t extend overall survival when combined with Roche Holding AG’s Avastin in patients with a form of lung tumor.
Two more clinical trials go against Lilly
In the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company suffered two other setbacks with former stars of its pipeline.
Eli Lilly’s top lawyer to retire at end of year
Indianapolis-based drugmaker Eli Lilly and Co. said Thursday its general counsel, Robert Armitage, will retire at the end of the year and be replaced by deputy general counsel Michael Harrington.
Lilly stops testing of experimental schizophrenia drug
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
Lilly’s Alzheimer’s finding triggers investor hope, doctor caution
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
Lilly wins appeal upholding patent for Alimta cancer drug
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
Alzheimer’s drug results leave Lilly ‘excited’ but uncertain
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
Lilly’s Alzheimer’s drug trials show mixed results
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
Alzheimer’s quest puts Lilly to test
Odds are long that Eli Lilly and Co.’s leading Alzheimer’s drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
Lilly to book $790M Amylin payment in third quarter
Eli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former drug development partner Amylin Pharmaceuticals.
Lilly stock slips after competitors halt Alzheimer’s plans
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
Lilly studying how dogs sense diabetes in humans
The Indianapolis drugmaker said its scientists are investigating whether dogs' sharp sense of smell allow them to detect changes in human chemistry.
Lilly braces for decline in Europe
Austerity and upheaval in Europe have not hurt Eli Lilly and Co.’s $4 billion-a-year drug business there, but the company is moving forward with plans to survive a coming swoon anyway.
Lilly’s quarterly profit falls, but tops analyst expectations
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
Potential Alzheimer’s drug fails first of four key trials
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
Potential Lilly antipsychotic falls short in study
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
Competing Alzheimer’s treatments facing long odds
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
Lilly gets 6-month Cymbalta marketing extension
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.